Embed Size (px)
Citation preview
DISCLAIMER
Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risksand uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive
COMPANY OVERVIEW
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused ondeveloping and commercializing therapies to treat targeted patient populations thatare suffering from serious diseases with a high unmet medical need. The companyis currently developing voclosporin, an investigational drug, for the potentialtreatment of lupus nephritis, focal segmental glomerulosclerosis, and Dry EyeSyndrome. The company is headquartered in Victoria, British Columbia and focusesits development efforts globally.
RECENT NEWS
Aurinia Pharmaceuticals to Release Third Quarter Financial Results andGeneral Business Updates on November 8, 2018Oct 25 2018, 7:00 AM EDT
Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial forthe Treatment of Lupus NephritisSep 25 2018, 4:01 PM EDT
Aurinia to Participate in Upcoming Investor ConferencesSep 19 2018, 4:01 PM EDT
Symbol AUPH
Exchange Nasdaq
Market Cap 464.16m
Last Price $5.44
52-Week Range $4.41 - $6.69
STOCK OVERVIEW INVESTOR RELATIONS
Celia EconomidesVice President, Public [email protected]
MANAGEMENT TEAM
Richard M. Glickman, L.L.D. (Hon)CEO & Chairman of the Board
Neil Solomons, M.D.Chief Medical Officer
Michael MartinChief Operating Officer
Dennis BourgeaultChief Financial Officer
Robert Huizinga, Ph.D., R.N.,CNeph(C)Executive Vice President, CorporateDevelopment
Erik Eglite, D.P.M., J.D., M.B.A.Senior Vice President, General Counsel &Chief Corporate Compliance Officer
Rashieda GluckSenior Vice President, Global ClinicalOperations
Ron DemersVice President, Manufacturing and SupplyChain
Celia EconomidesVice President, Corporate & Public Affairs
Lawrence (Larry) D. MandtVice President, Quality & Regulatory Affairs
Bradley J. DickersonGeneral Manager, Americas & GlobalCommercial Lead
Sue Evans, MBA, RACHead, Regulatory Affairs
Simrat Randhawa, M.D., M.B.A.Head of Global Medical Affairs
AURINIA PHARMACEUTICALSINC.
#1203-4464 Markham Street Victoria, BC V8Z 7X8 Canada
factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it'squarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brandname are the property of their respective companies.
